Overview
Yoshihiro Minamiya practices in Hondo, Japan. Mr. Minamiya is highly rated in 5 conditions, according to our data. His top areas of expertise are Lung Cancer, Esophageal Cancer, Lung Adenocarcinoma, Lymphadenectomy, and Endoscopy.
His clinical research consists of co-authoring 172 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Lung CancerMr. Minamiya isDistinguished. Learn about Lung Cancer.
- Advanced
- Esophageal CancerMr. Minamiya isAdvanced. Learn about Esophageal Cancer.
- Lung AdenocarcinomaMr. Minamiya isAdvanced. Learn about Lung Adenocarcinoma.
- Mediastinal TumorMr. Minamiya isAdvanced. Learn about Mediastinal Tumor.
- Non-Small Cell Lung Cancer (NSCLC)Mr. Minamiya isAdvanced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Experienced
- Adult Soft Tissue SarcomaMr. Minamiya isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Brain TumorMr. Minamiya isExperienced. Learn about Brain Tumor.
- Breast CancerMr. Minamiya isExperienced. Learn about Breast Cancer.
- Breast Cancer in MenMr. Minamiya isExperienced. Learn about Breast Cancer in Men.
- Cerebral Cavernous MalformationMr. Minamiya isExperienced. Learn about Cerebral Cavernous Malformation.
- EGFR Positive Lung CancerMr. Minamiya isExperienced. Learn about EGFR Positive Lung Cancer.